drugset / Trial / NCT05046314
A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
This study is a multicenter, single-arm, open-label Phase II clinical trial evaluating TK216 in combination with vincristine in the treatment of relapsed or refractory Ewing sarcoma (ES) including Ewing's sarcoma family tumors (ESFTs).
Timeline
- Start
- 2024-03-12
- Primary completion
- 2025-02-05
- Completion
- 2025-02-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TK216 | Unknown | — | — |
| Background | Vincristine | Small molecule | 1.5 mg/m2 | — |